About Abnova

  • Where to buy
  • Choose your location

Press Release: Abnova & Ardic Instruments Introduce New Fiber-Optic Protein Quantification System for Research and In Vitro Diagnostic (IVD) Markets

Press Release: Abnova & Ardic Instruments Introduce New Fiber-Optic Protein Quantification System for Research and In Vitro Diagnostic (IVD) Markets

Abnova & Ardic Instruments Introduce New Fiber-Optic Protein Quantification System for Research and In Vitro Diagnostic (IVD) Markets

Neihu, Taiwan (June 15, 2011)

Abnova Corporation and Ardic Instruments announced today the collaboration and introduction of a label-free, protein detection platform based on a new fiber-optic particle, plasmon resonance (FO-PPR) system. This new protein platform opens up several avenues of applications ranging from protein quantification to protein-protein/protein-small molecule interactions to kinetic measurements. Most importantly, the FO-PPR technology addresses an unmet need for higher sensitivity, protein quantification using a stand-alone, capturing antibody. In contrast, the conventional sandwich ELISA platform requires both capturing and detection antibody for protein detection. It is also handicapped by a limited dynamic range and inadequate sensitivity to measure many biologically and clinically relevant biomolecules at wide-apart and lower physiologic concentrations. Collectively, these attributes undermine sandwich ELISA platform in today’s fast-paced yet highly demanding translational research, preclinical and clinical settings. Abnova and Ardic collaboration aims to leverage each other’s expertise in reagent manufacturing and instrument engineering to provide an integrated solution for label-free, protein quantification markets. A point-of-care, IVD system based on FO-PPR technology for H1N1 influenza virus detection will be introduced at the upcoming American Academy Clinical Chemistry conference in Atlanta, GA in July. Both companies will work together to navigate the influenza test through the regulatory track in Taiwan. Moreover, an open system for the research market would be available before the end of the year for worldwide sales by Abnova.

“We are very excited to have the opportunity to collaborate with Ardic to introduce an unprecedented label-free system for the biotech industry,” said Dr. Wilber Huang, President and CEO of Abnova. Ardic, has assembled an outstanding team of optical, microfluidic, and electrical engineers with knowledge and expertise that rivals the counterparts in the US and Europe. The use of fiber-optic technology remarkably improved the performance of the traditional plasma resonance technology by obviating high cost optical alignment while increasing the sensitivity by implementing a 3-D (instead of 2-D) detection environment and decreasing the background noise by partitioning the optical signal and the biochemical reaction. Moreover, the use of the plasmon resonance is amenable to real-time and kinetic measurements. “We have tested the performance of the FO-PPR system using Abnova’s pre-validated H1N1 reagents. The convenience of single capturing antibody for virus detection means that the system is well-positioned to monitor the high frequency of viral protein changes inherent in the seasonal or pandemic influenza outbreaks. As for the research market, Abnova aims to validate a large collection of antibodies so that the customers can readily purchase established reagents off-the-shelf for convenience and ease-of-use.”

“As an instrument developer, we are eager to work with an antibody reagent manufacturer like Abnova,” stated Dr. Jerome Shen, President & CEO of Ardic Instruments. “Being a pioneer in this new field of FO-PPR, we are keen to have the largest possible applications available to the customers to capture a greater market share in today’s competitive landscape. Abnova has dedicated and well-experienced in-house teams for antibody manufacturing, assay development, and instrument integration including software. This effectively decreases the cycle time required to bring an integrated product to market. H1N1 influenza testing serves a model system for our initial infectious IVD application. We would like to extend this application to other infectious agents and also cancer biomarkers, by taking full advantage of our system’s performance. The research space is highly appealing to us because it is a conduit for our system to start penetrating and capturing sales without regulatory approval processes required by IVD market. Hence, Abnova can effectively complement our immediate quest in the research market.”


About Ardic Instruments

ARDIC Instruments offers a pipeline of analytical instruments for educational, research, and industrial applications in nanotechnology. Ardic’s core technologies enable the development of a range of analytical products and peripherals that are competitive in terms of cost, reliability, precision, and accuracy. The main product line focuses on scanning probe microscopy (SPM), optical profilometers, and fiber-optic particle plasmon resonance (FO-PPR). Our mission is to build Taiwan's first internationally recognized analytical instruments company through emphasis in quality, precision, and service. (www.ardicinstruments.com)

About Abnova

Abnova is a biotech company specializing in high throughput monoclonal antibody production. The infrastructure Abnova has developed is a unique combination of world-class technologies and management experience of the IT industry in Taiwan. The company has vastly expanded the scope and availability of bio-tools reagents by taking a genome-wide approach to the production of human recombinant protein and antibody. Abnova has developed a portfolio of integrated and system applications including antibody pairs, ELISA kits, assays, and FISH probes which are essential to the biomarker discovery and translational research institutes. Abnova also has in vitro diagnostic programs focusing on diabetes, infection, and cancer, and fully human antibody therapeutic for the treatment of sepsis. (www.abnova.com)
  • RSS
  • YouTube
  • Linkedin
  • Facebook